In conjunction with the sublicensing agreement, Topica Pharmaceuticals will now focus on developing Luliconazole exclusively for the treatment of onychomycosis.
Reportedly, in February of 2010 the company’s IND for onychomycosis was opened, paving the way for human clinical trials to begin later in 2010.
Topica Pharma president and CEO Greg Vontz they are looking forward to the initiation of Luliconazole’s clinical development program this fall and validating the molecule’s promising preclinical profile in onychomycosis.
“If the molecule’s preclinical profile is validated, Luliconazole has the potential to be the first truly effective, safe and convenient topical therapy for onychomycosis; providing physicians and patients with a much needed alternative to currently available oral anti-fungal therapies that have risk of serious adverse events, Vontz said.